{"article_id": "BIO_q3_2020.txt", "article": ["net sales for the third quarter of 2020 were $ 647.3 million , which is a 15.5 % increase on a reported basis versus $ 560.6 million in q3 of 2019 .", "on a currency neutral basis , sales increased 14.9 % .", "generally , we are seeing most academic and diagnostics labs now running between 70 % and 90 % capacity and slowly continuing to improve .", "biopharma labs are broadly running at a slightly higher capacity rate of 80 % to 90 % and we continue to monitor the situation closely .", "we estimate that covid - 19 - related sales were about $ 98 million in the quarter .", "sales of the life science group in the third quarter of 2020 were $ 324 million compared to $ 215.7 million in q3 of 2019 , which is a 50.2 % increase on a reported basis and a 48.8 % increase on a currency neutral basis .", "excluding process media sales , the life science business grew 53 % on a currency neutral basis versus q3 of 2019 .", "in addition , last month we launched two new pcr systems , the cfx opus 96 and the cfx opus 384 , which strengthens our global response and contribution to the fight against the pandemic .", "sales of clinical diagnostics products in the third quarter were $ 322.2 million compared to $ 341.8 million in q3 of 2019 , which is a 5.7 % decline on a reported basis and a 5.9 % decline on a currency neutral basis .", "the reported gross margin for the third quarter of 2020 was 56.7 % on a gaap basis and compares to 54.8 % in q3 of 2019 .", "amortization related to prior acquisitions recorded in cost of goods sold was $ 4.8 million compared to $ 3.9 million in q3 of 2019 .", "sg&a expenses for q3 of 2020 were $ 198.2 million or 30.6 % of sales compared to $ 201.6 million or 36 % in q3 of 2019 .", "total amortization expense related to acquisitions recorded in sg&a for the quarter was $ 2.3 million versus $ 1.9 million in q3 of 2019 .", "research and development expense in q3 was $ 59.5 million or 9.2 % of sales compared to $ 47.9 million or 8.6 % of sales in q3 of 2019 .", "q3 operating income was $ 109.6 million or 16.9 % of sales compared to $ 57.5 million or 10.2 % of sales in q3 of 2019 .", "looking below the operating line , the change in fair market value of equity securities holdings added $ 1,580 million of income to the reported results , and is substantially related to holdings of the shares of sartorius ag .", "also during the quarter , interest and other income resulted in a net expense of $ 5.5 million compared to $ 2.1 million of expense last year .", "the effective tax rate for the quarter was 21.9 % compared to 22.8 % in q3 of 2019 .", "reported net income for the third quarter was $ 1,315 million and diluted earnings per share were $ 43.64 .", "looking at the non-gaap results for the third quarter , in cost of goods sold , we have excluded $ 4.8 million of amortization of purchased intangibles and a small restructuring benefits .", "these exclusions moved the gross margin for the third quarter of 2020 to a non-gaap gross margin of 57.5 % versus 56 % in q3 of 2019 .", "non-gaap sg&a in the third quarter of 2020 was 29.4 % versus 35.5 % in q3 of 2019 .", "in sg&a , on a non-gaap basis , we have excluded amortization of purchased intangibles of $ 2.3 million , legal related expenses of $ 6 million and restructuring and acquisition - related benefits of less than $ 1 million .", "non-gaap r&d expense in the third quarter of 2020 was 9.2 % versus 8.5 % in q3 of 2019 .", "the cumulative sum of these non-gaap adjustments result in moving the quarterly operating margin from 16.9 % on a gaap basis to 18.8 % on a non-gaap basis .", "these non-gaap operating margin compares to a non-gaap operating margin in q3 of 2019 of 12 % .", "we have also excluded certain items below the operating line , which are the increase in value of the sartorius equity holdings of 1,580 million and a small loss associated with venture investments .", "the non-gaap effective tax rate for the quarter was 22.5 % compared to 25.5 % in q3 of 2019 .", "we now estimate the full year tax rate on a non-gaap basis to be approximately 24 % .", "and finally , non-gaap net income for the third quarter of 2020 was $ 90.3 million or $ 3 diluted earnings per share compared to $ 48.6 million and $ 1.61 per share in q3 of 2019 .", "total cash and short - term investments at the end of q3 were $ 1,160 million , an increase of $ 123 million from the end of q2 of 2020 .", "during the third quarter , our inventory increased by about $ 12 million from the second quarter of 2020 .", "we plan to use the cash on hand to repay the $ 425 million of outstanding senior notes in december .", "in addition , the market value of our holdings in sartorius ag has increased , which technically may deem us as an investment company under the 1940 investment company act .", "during the third quarter , we did not purchase any shares of our stock , we had a total of $ 273 million available for potential share buybacks .", "for the third quarter of 2020 , net cash generated from operating activities was $ 135.7 million , which compares to $ 99.8 million in q3 of 2019 .", "the adjusted ebitda for the third quarter of 2020 was 22.9 % of sales .", "the adjusted ebitda in q3 of 2019 was 17 % .", "net capital expenditures for the third quarter of 2020 were $ 20 million and depreciation and amortization for the third quarter was $ 33.7 million .", "we project that the full - year capex spend will likely be between $ 80 million and $ 90 million .", "with that in mind , we currently believe that the full year 2020 year - over - year currency - neutral sales to be up 5.9 % to 6.3 % .", "we estimate 27 % to 28 % currency - neutral revenue growth for life science and estimate about 7 % currency - neutral revenue decline for the diagnostics group in 2020 .", "full year non-gaap gross margin is projected to be between 56.5 % and 57 % .", "r&d is around 9 % .", "full year gaap operating margin between 16 % and 16.5 % and full - year adjusted ebitda margin to be between 21 % and 21.5 % ."], "summary_gold": "q3 earnings per share $ 43.64 .<q>q3 sales $ 647.3 million versus refinitiv ibes estimate of $ 570.6 million .<q>bio rad laboratories - currently believes full - year 2020 yoy currency - neutral sales may be up 5.9 to 6.3 percent .", "summary_pred": "in addition , the market value of our holdings in sartorius ag has increased , which technically may deem us as an investment company under the 1940 investment company act .<q>research and development expense in q3 was $ 59.5 million or 9.2 % of sales compared to $ 47.9 million or 8.6 % of sales in q3 of 2019 .<q>during the third quarter , our inventory increased by about $ 12 million from the second quarter of 2020 .<q>we estimate 27 % to 28 % currency - neutral revenue growth for life science and estimate about 7 % currency - neutral revenue decline for the diagnostics group in 2020 .<q>we plan to use the cash on hand to repay the $ 425 million of outstanding senior notes in december .<q>we now estimate the full year tax rate on a non-gaap basis to be approximately 24 % .<q>we project that the full - year capex spend will likely be between $ 80 million and $ 90 million .<q>r&d is around 9 % .<q>full year non-gaap gross margin is projected to be between 56.5 % and 57 % .<q>we estimate that covid - 19 - related sales were about $ 98 million in the quarter .<q>generally , we are seeing most academic and diagnostics labs now running between 70 % and 90 % capacity and slowly continuing to improve .<q>biopharma labs are broadly running at a slightly higher capacity rate of 80 % to 90 % and we continue to monitor the situation closely .<q>on a currency neutral basis , sales increased 14.9 % .<q>we have also excluded certain items below the operating line , which are the increase in value of the sartorius equity holdings of 1,580 million and a small loss associated with venture investments .", "len_article": 45, "len_summary_gold": 3, "len_summary_pred": 14, "len_sent_scores": 45}